These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 7537801)

  • 1. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups.
    Steyerberg EW; Keizer HJ; Fosså SD; Sleijfer DT; Toner GC; Schraffordt Koops H; Mulders PF; Messemer JE; Ney K; Donohue JP
    J Clin Oncol; 1995 May; 13(5):1177-87. PubMed ID: 7537801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Prediction of histology. ReHiT Study Group.
    Steyerberg EW; Keizer HJ; Messemer JE; Toner GC; Schraffordt Koops H; Fosså SD; Gerl A; Sleijfer DT; Donohue JP; Habbema JD
    Cancer; 1997 Jan; 79(2):345-55. PubMed ID: 9010108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer.
    Steyerberg EW; Gerl A; Fossá SD; Sleijfer DT; de Wit R; Kirkels WJ; Schmeller N; Clemm C; Habbema JD; Keizer HJ
    J Clin Oncol; 1998 Jan; 16(1):269-74. PubMed ID: 9440752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retroperitoneal metastases in testicular cancer: role of CT measurements of residual masses in decision making for resection after chemotherapy.
    Steyerberg EW; Keizer HJ; Sleijfer DT; Fossâ SD; Bajorin DF; Gerl A; de Wit R; Kirkels WJ; Koops HS; Habbema JD
    Radiology; 2000 May; 215(2):437-44. PubMed ID: 10796922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors in metastatic nonseminomatous germ cell tumours.
    Hanson PR; Belitsky P; Millard OH; Lannon SG
    Can J Surg; 1993 Dec; 36(6):537-40. PubMed ID: 7504978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors.
    Aprikian AG; Herr HW; Bajorin DF; Bosl GJ
    Cancer; 1994 Aug; 74(4):1329-34. PubMed ID: 8055456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Re-analysis of Histology in Testicular Cancer (ReHiT) Study Group.
    Steyerberg EW; Donohue JP; Gerl A; Toner GC; Schraffordt Koops H; Fosså SD; Keizer HJ
    J Urol; 1997 Aug; 158(2):474-8. PubMed ID: 9224327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. Swedish-Norwegian Testicular Cancer Group.
    Klepp O; Olsson AM; Henrikson H; Aass N; Dahl O; Stenwig AE; Persson BE; Cavallin-Ståhl E; Fosså SD; Wahlqvist L
    J Clin Oncol; 1990 Mar; 8(3):509-18. PubMed ID: 1689773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular cancer.
    Steyerberg EW; Keizer HJ; Fosså SD; Sleijfer DT; Bajorin DF; Donohue JP; Habbema JD
    Br J Cancer; 1996 Nov; 74(9):1492-8. PubMed ID: 8912551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
    Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
    Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of a prediction model and its predictors for the histology of residual masses in nonseminomatous testicular cancer.
    Vergouwe Y; Steyerberg EW; Foster RS; Habbema JD; Donohue JP
    J Urol; 2001 Jan; 165(1):84-8; discussion 88. PubMed ID: 11125370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thoracotomy for postchemotherapy resection of pulmonary residual tumor mass in patients with nonseminomatous testicular germ cell tumors: aggressive surgical resection is justified.
    Gels ME; Hoekstra HJ; Sleijfer DT; Nijboer AP; Molenaar WM; Ebels T; Schraffordt Koops H
    Chest; 1997 Oct; 112(4):967-73. PubMed ID: 9377960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
    Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
    J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resection of small, residual retroperitoneal masses after chemotherapy for nonseminomatous testicular cancer: a decision analysis.
    Steyerberg EW; Marshall PB; Keizer HJ; Habbema JD
    Cancer; 1999 Mar; 85(6):1331-41. PubMed ID: 10189139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: a quantitative overview of 996 resections.
    Steyerberg EW; Keizer HJ; Stoter G; Habbema JD
    Eur J Cancer; 1994; 30A(9):1231-9. PubMed ID: 7999405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nodule Size After Chemotherapy and Primary-Tumor Teratoma Components Predict Malignancy of Residual Pulmonary Nodules in Metastatic Nonseminomatous Germ Cell Tumor.
    Toyoshima Y; Hara T; Matsui Y; Nagumo Y; Maejima A; Shinoda Y; Komiyama M; Watanabe SI; Fujimoto H
    Ann Surg Oncol; 2018 Nov; 25(12):3668-3675. PubMed ID: 30191415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy.
    Eastham JA; Wilson TG; Russell C; Ahlering TE; Skinner DG
    Urology; 1994 Jan; 43(1):74-80. PubMed ID: 7506856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testicular tumors: residual retroperitoneal mass surgery after chemotherapy;Is it possible to predict their histology?
    Medina-Polo J; Martínez-Silva V; Domínguez-Esteban M; de la Rosa-Kehrmann F; Villacampa-Aubá F; Castellano-Gauna D; Díaz-González R
    Arch Esp Urol; 2011 Sep; 64(7):611-9. PubMed ID: 21965259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours.
    Hartmann JT; Candelaria M; Kuczyk MA; Schmoll HJ; Bokemeyer C
    Eur J Cancer; 1997 May; 33(6):843-7. PubMed ID: 9291803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicentre validation with more than 1000 patients.
    Vergouwe Y; Steyerberg EW; Foster RS; Sleijfer DT; Fosså SD; Gerl A; de Wit R; Roberts JT; Habbema JD
    Eur Urol; 2007 Feb; 51(2):424-32. PubMed ID: 16911854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.